According to reports from Moneycontrol, Prabhudas Lilladher has maintained a 'HOLD' rating on Jubilant Ingrevia with a target price of ₹657. The brokerage's research report dated February 05, 2026, recommends this valuation based on the Sum-of-the-Parts (SOTP) approach. The target price represents an implied valuation of 27x December 2027 EPS for the company.
As reported by Moneycontrol, JUBLINGR reported a consolidated revenue of ₹10.5 billion in Q3 FY26, which was broadly in line with analyst estimates. The Chemical Intermediate segment experienced a 14% quarter-on-quarter decline and 2% year-on-year decrease due to pricing pressure across core products. In contrast, the Nutrition & Health Solution segment demonstrated strong growth with an 11% QoQ increase and 6% YoY growth, driven by increased volume of Vitamin B3. The company's Q3 PAT is expected to dip 48.8% YoY to ₹46.8 crore according to latest projections.
According to the research report, the Specialty segment showed mixed results with the pharma portfolio experiencing improved demand and stable pricing, while the Agrochemical segment remained weak due to softening in pyridine and its derivative prices. Deliveries under the USD 300 million agrochemical CDMO contract are expected to commence in this quarter. On the margin front, Chemical Intermediates and Nutrition segments witnessed a 170 basis points year-on-year decline, while Specialty segment saw a 40 basis points quarter-on-quarter and 50 basis points year-on-year decline.
As reported by Moneycontrol, looking ahead, the brokerage expects the Specialty segment to remain the key growth driver for Jubilant Ingrevia. However, pricing headwinds in the Nutrition and Chemical Intermediates segments continue to pose challenges for the company. The company's performance reflects the broader market dynamics affecting pricing across different business segments in the current market environment.
